Challenges in assessing outcomes for pediatric asthma

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 5, 2001, Pages

  Szefler, Stanley J ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Chronic inflammation; Inhaled glucocorticoids; Natural history; Nonsteroid controller medications; Pulmonary function; Surrogate markers

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ARTICLE; ASTHMA; BONE DENSITY; CHILDHOOD DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DRUG SAFETY; GROWTH INHIBITION; HUMAN; INFLAMMATION; LONG TERM CARE; LUNG FUNCTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

EID: 0035012403     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.114947     Document Type: Article

References (28)

1. National Asthma Education and Prevention Program. Expert Panel Report 2: Clinical Practice Guidelines: Guidelines for the Diagnosis and Management of Asthma. Rockville (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; July 1997. NIH Publication No. 98-051.
2. Childhood Asthma Management Program Research Group. Design and implementation of a patient education center for the Childhood Asthma Management Program. Ann Allergy Asthma Immunol 1998;81:571-81.
3. Global Initiatives for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Heart, Lung, and Blood Institute; November 1998. NIH Publication No. 96-3659B.
4. Peat JK. Asthma: A longitudinal perspective. J Asthma 1998;35:235-41.
5. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995;181:33-40.
6. Lee TH, Brattsand R, Leung D. Corticosteroid action and resistance in asthma. Am J Respir Crit Care Med 1996;154:S1-S79.
7. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737-43.
8. Vrugt B, Wilson S, Underwood J, Bron A, de Bruyn R, Bradding P, et al. Mucosal inflammation in severe glucocorticoiddependent asthma. Eur Respir J 1999;13:1245-52.
9. Szefler SJ. Asthma: The new advances. Adv Pediatr 2000;47:273-308.
10. Weiss ST. Early life predictors of adult chronic obstructive lung disease. Eur Respir Rev 1995;31:303-9.
11. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200.
12. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-81.
13. Haahtela T, Jarvinen M, Kava T, Kirviranta K, Koskinen S, Lehtonen K. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
14. Selroos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995;108:1228-34.
15. Overbeek SE, Kerstjens HA, Bogaard JM, Mulder PG, Postma DS. Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest 1996;110:35-41.
16. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997;156:951-8.
17. Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A placebo-controlled study. Am J Respir Crit Care Med 1997;155:1864-71.
18. Kennis T. Inhaled corticosteroids: The FDA takes another look. Ann Allergy Asthma Immunol 1998;81:406-10.
19. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334-9.
20. DuBuske LM, Grossman J, Dube LM, Swanson LJ, Lancaster JF. Randomized trial of zileuton in patients with moderate asthma: Effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms: Zileuton Study Group. Am J Managed Care 1997;3:633-40.
21. In KH, Asano K, Beier D, Gobholz J, Finn PW, Silverman EK. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
22. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: Implications for practice. Pediatr Clin North Am 1997;44:55-77.
23. Wanner A, Boushey HA, Lee TH, et al. The genetics of asthma. Am J Respir Crit Care Med 1997;156:S67-S162.
24. Roses AD. Pharmacogenetics and future drug development. Lancet 2000;355:1358-61.
25. Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999;103:376-87.
26. Kemp J, Wanderer AA, Ramsdell J, Southern DL, Weiss S, Aaronson D, et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1998;82:463-71.
27. Larsen GL. Focusing on childhood asthma: The childhood asthma management program (CAMP). J Allergy Clin Immunol 1999;103:371-3.
28. Long-term effects of budesonide or nedocromil in children with asthma: The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343:1054-63.